The death of a participant in a gene therapy trial has thrown the entire field into question–as it did once before in 1999. Can the field survive this second setback? Virginia Hughes investigates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
https://doi.org/10.1038/news060424-14
Genetic patch treats 'bubble-boy' disease
Gene therapy put on hold as third child develops cancer
Sanctions agreed over teenager's gene-therapy death
Related external links
Targeted Genetics response to allegations
Rights and permissions
About this article
Cite this article
Hughes, V. Therapy on trial. Nat Med 13, 1008–1009 (2007). https://doi.org/10.1038/nm0907-1008
Published:
Issue date:
DOI: https://doi.org/10.1038/nm0907-1008
This article is cited by
-
How not to be seen: immune-evasion strategies in gene therapy
Gene Therapy (2008)
